Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Microbot Medical ( (MBOT) ) has provided an update.
On March 4, 2025, Microbot Medical Inc. announced the appointment of Paul Mullen as Vice President of Sales, marking the company’s first commercial hire as it prepares for the anticipated FDA clearance of its LIBERTY® Endovascular Robotic System in the second quarter of 2025. Mullen, with a strong background in endovascular sales and market development, will lead the company’s U.S. commercial sales efforts, focusing on building the sales strategy and infrastructure needed for a successful product launch.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics. The company is developing the world’s first single-use, fully disposable endovascular robotic system, aiming to improve the quality of care for patients and providers globally by making advanced robotic technologies more accessible in the endovascular space.
YTD Price Performance: 23.68%
Average Trading Volume: 4,169,650
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $48.99M
See more data about MBOT stock on TipRanks’ Stock Analysis page.